Gary L. Rosner

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

Patrick M. Forde, Jamie E. Chaft, Kellie N. Smith et al. · New England Journal of Medicine · 2018 · 2.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Mark J. Ratain, Tim Eisen, Walter M. Stadler et al. · Journal of Clinical Oncology · 2006 · 1K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

MGMT Promoter Methylation and Field Defect in Sporadic Colorectal Cancer

Lanlan Shen, Yutaka Kondo, Gary L. Rosner et al. · JNCI Journal of the National Cancer Institute · 2005 · 498 citations · Full text

Medicine, Molecular Biology, Oncology +17

Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia

Guillermo Garcia‐Manero, Hagop M. Kantarjian, Blanca Sánchez‐González et al. · Blood · 2006 · 468 citations · Full text

Medicine, Oncology, Pharmacology +10

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

Guillermo Garcia‐Manero, Hui Yang, Carlos E. Bueso‐Ramos et al. · Blood · 2007 · 461 citations

Medicine, Hematology, Oncology +16